Drugmaker Geron Gets Investor Suit Over Slowing Growth Dismissed

Geron Corp. investors failed to allege false statements and fraudulent intent by the drugmaker’s leaders about sales growth, a federal court said Monday.

A December 2024 statement touting “strong continued growth” is the basis of the investors’ strongest claim, but they have only an uncorroborated statement suggesting that sales had flattened by that time, Judge Vince Chhabria said for the US District Court for the Northern District of California. Chhabria dismissed the complaint with a chance to re-plead.

• The investors alleged the company misled them about their expectations for the launch and growth potential of Rytelo, a drug used to ...